Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Elena Mairinger"'
Autor:
Elena Mairinger, Michael Wessolly, Paul Buderath, Sabrina Borchert, Larissa Henrich, Pawel Mach, Julia Steinborn, Rainer Kimming, Bharat Jasani, Kurt Werner Schmid, Agnes Bankfalvi, Fabian Dominik Mairinger
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe underlying mechanism of high T-cell presence as a favorable prognostic factor in high-grade serous ovarian carcinoma (HGSOC) is not yet understood. In addition to immune cells, various cofactors are essential for immune processes. One o
Externí odkaz:
https://doaj.org/article/61da0f0817b3496bb034186b8ace0936
Autor:
Michael Wessolly, Susann Stephan-Falkenau, Anna Streubel, Marcel Wiesweg, Sabrina Borchert, Elena Mairinger, Jens Kollmeier, Henning Reis, Torsten Bauer, Kurt Werner Schmid, Thomas Mairinger, Martin Schuler, Fabian D. Mairinger
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background Immune checkpoint inhibitors (ICIs) are currently one of the most promising therapy options in the field of oncology. Although the first pivotal ICI trial results were published in 2011, few biomarkers exist to predict their thera
Externí odkaz:
https://doaj.org/article/ba9aee6c71794d6f8106a205ed38e4c9
Autor:
Michael Wessolly, Elena Mairinger, Sabrina Borchert, Agnes Bankfalvi, Pawel Mach, Kurt Werner Schmid, Rainer Kimmig, Paul Buderath, Fabian Dominik Mairinger
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundHigh-grade serous ovarian cancer (HGSOC) is the predominant and deadliest form of ovarian cancer. Some of its histological subtypes can be distinguished by frequent occurrence of cancer-associated myofibroblasts (CAFs) and desmoplastic stro
Externí odkaz:
https://doaj.org/article/2d03341162de4358a573bb7f97a982f0
Autor:
Sabrina Borchert, Michael Wessolly, Jan Schmeller, Elena Mairinger, Jens Kollmeier, Thomas Hager, Thomas Mairinger, Thomas Herold, Daniel C. Christoph, Robert F. H. Walter, Wilfried E. E. Eberhardt, Till Plönes, Jeremias Wohlschlaeger, Clemens Aigner, Kurt Werner Schmid, Fabian D. Mairinger
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
Abstract Background Malignant pleural mesothelioma (MPM) is a tumour arising from pleural cavities with poor prognosis. Multimodality treatment with pemetrexed combined with cisplatin shows unsatisfying response-rates of 40%. The reasons for the rath
Externí odkaz:
https://doaj.org/article/a78dfbb5af2449eea6d8fb6a3f276409
Autor:
Alexander Mathilakathu, Michael Wessolly, Elena Mairinger, Hendrik Uebner, Daniel Kreidt, Luka Brcic, Julia Steinborn, Kristina Greimelmaier, Jeremias Wohlschlaeger, Kurt Werner Schmid, Fabian D. Mairinger, Sabrina Borchert
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 6; Pages: 3278
Background: Malignant pleural mesothelioma (MPM) has an infaust prognosis due to resistance to systemic treatment with platin-analoga. MPM cells modulate the immune response to their benefit. They release proinflammatory cytokines, such as TGF-ß, aw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f626a8f7d9941e813a7c96350b2c671
https://pubmed.ncbi.nlm.nih.gov/35328699
https://pubmed.ncbi.nlm.nih.gov/35328699
Autor:
Thomas Herold, Wildfried E. E. Eberhardt, Pia-Maria Suckrau, Jeremias Wohlschlaeger, Clemens Aigner, Kurt Werner Schmid, Agnes Bankfalvi, Michael Wessolly, Fabian Dominik Mairinger, Robert Fred Henry Walter, Elena Mairinger, Balazs Hegedus, Thomas Hager, Sabrina Borchert
Publikováno v:
Journal of Oncology, Vol 2019 (2019)
Journal of Oncology
Journal of Oncology
Background. Malignant pleural mesothelioma (MPM) is a rare, predominantly asbestos-related and biologically highly aggressive tumor associated with a dismal prognosis. Multimodal therapy consisting of platinum-based chemotherapy is the treatment of c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b0c8a4ac774f736984f0d5f26ef6fda
https://doi.org/10.1155/2019/2902985
https://doi.org/10.1155/2019/2902985
Autor:
Michael Wessolly, Susann Stephan-Falkenau, Anna Streubel, Marcel Wiesweg, Sabrina Borchert, Elena Mairinger, Jens Kollmeier, Henning Reis, Torsten Bauer, Kurt Werner Schmid, Thomas Mairinger, Martin Schuler, Fabian D. Mairinger
Publikováno v:
BMC Cancer
BMC Cancer, Vol 22, Iss 1, Pp 1-13 (2022)
BMC Cancer, Vol 22, Iss 1, Pp 1-13 (2022)
Background Immune checkpoint inhibitors (ICIs) are currently one of the most promising therapy options in the field of oncology. Although the first pivotal ICI trial results were published in 2011, few biomarkers exist to predict their therapy outcom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ffce579c84d14134fc09ed2afd2bef7
https://pubmed.ncbi.nlm.nih.gov/34996407
https://pubmed.ncbi.nlm.nih.gov/34996407
Autor:
Luka Brcic, Sabrina Borchert, Thomas Mairinger, Julia Steinborn, Robert Fred Henry Walter, Michael Wessolly, Hendrik Beckert, Fabian Dominik Mairinger, Jeremias Wohlschlaeger, Elena Mairinger, Thomas Hager, Daniel C. Christoph, Kurt Werner Schmid, Alexander Mathilakathu, Jens Kollmeier
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare malignant tumor associated with asbestos exposure, with infaust prognosis and overall survival below 20 months in treated patients. Platinum is still the backbone of the chemotherapy protocol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e642138cbc12b2fc1a085c7b6a27fb0d
Autor:
Elena Mairinger, Thomas Herold, Balazs Hegedus, Michael Wessolly, Robert Fred Henry Walter, Julia Steinborn, Thomas Hager, Fabian Dominik Mairinger, Sabrina Borchert, Kurt Werner Schmid, Clemens Aigner, Agnes Bankfalvi, Wilfried Eberhardt, Jeremias Wohlschlaeger, Pia-Maria Suckrau
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Malignant pleural mesothelioma (MPM) is a rare, but aggressive tumor with dismal prognosis. Platinum-based chemotherapy is regularly used as part of multimodality therapy. The expression of metallothioneins (MT) has been identified as a reason for ci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b5d372e60cbfe5b2f258716c18269c5
https://doi.org/10.1038/s41598-020-75807-x
https://doi.org/10.1038/s41598-020-75807-x
Autor:
Michael, Wessolly, Susann, Stephan-Falkenau, Anna, Streubel, Robert, Werner, Sabrina, Borchert, Sergej, Griff, Elena, Mairinger, Robert F H, Walter, Torsten, Bauer, Wilfried E E, Eberhardt, Torsten G, Blum, Kurt W, Schmid, Jens, Kollmeier, Thomas, Mairinger, Fabian D, Mairinger
Publikováno v:
Cancer Management and Research
Background Immune checkpoint inhibition, especially the blockade of PD-1 and PD-L1, has become one of the most thriving therapeutic approaches in modern oncology. Immune evasion caused by altered tumor epitope processing (so-called processing escapes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bac2b7003f79d12274b2196e815320fe
https://pubmed.ncbi.nlm.nih.gov/32922086
https://pubmed.ncbi.nlm.nih.gov/32922086